Morgan Stanley Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $596
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Erin Wright maintains an Overweight rating on IDEXX Laboratories (IDXX) but lowers the price target from $620 to $596.

May 14, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley maintains an Overweight rating on IDEXX Laboratories but reduces the price target from $620 to $596.
The adjustment in price target by a major analyst like Morgan Stanley can have a mixed impact. While maintaining an Overweight rating indicates a positive outlook on the stock, the reduction in price target could signal a tempered expectation for the stock's short-term growth potential. Investors might view this as a slight negative, but the overall bullish stance should mitigate any significant downside.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100